Jain Global’s Jazz Pharmaceuticals JAZZ Stock Holding History

Jain Global’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-35,375	Closed	-$6.01M	–	1436
2025 Q4	$6.01M	Buy	+35,375	New	+$5.42M	0.03%	404
2025 Q2	–	Sell	-58,481	Closed	-$6.35M	–	1400
2025 Q1	$7.26M	Buy	58,481 +39,175	+203%	+$5.11M	0.09%	173
2024 Q4	$2.38M	Buy	+19,306	New	+$2.28M	0.07%	212

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Jain Global's JAZZ Position: Q1 2026 in Review

Jain Global sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 35,375 shares — an estimated $6.01M sold.

Jain Global first reported a position in JAZZ in Q4 2024 and held it in 3 quarters. The position peaked at $7.26M in Q1 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Jain Global reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Jain Global sold 35,375 Jazz Pharmaceuticals shares in Q1 2026, an estimated $6.01M.
Jain Global first reported a position in Jazz Pharmaceuticals in Q4 2024 and held it in 3 quarters.
Jain Global's Jazz Pharmaceuticals position peaked at $7.26M in Q1 2025.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Jain Global's 13F filing for Q1 2026, filed 15 May 2026.